Frontiers in Oncology · 2023 · 16 citations · 40 references
MedicineMolecular BiologyOncologyEpigeneticsGene ExpressionMolecular OncologyCancer Cell SignalingCancer EpigeneticsCancer TranscriptomicsEpigenetic Alterations In CancerEpigenetic Regulation In CancerPancreatic CancerAberrant Dna MethylationDna MethyltransferasesEpigenetic RegulationMethylation PathwaysN6-methyladenosine RegulationP21 PathwayRna SequencingRna Sequencing (Rna-seq)
Background: Many studies have reported that N6-methyladenosine (m6A) modification plays a critical role in the epigenetic regulation of organisms and especially in the pathogenesis of malignant diseases. However, m6A research has mainly focused on methyltransferase activity mediated by METTL3, and few studies have focused on METTL16. The aim of this study was to investigate the mechanism of METTL16, which mediates m6A modification, and its role in pancreatic adenocarcinoma (PDAC) cell proliferation. Methods: Clinicopathologic and survival data were retrospectively collected from 175 PDAC patients from multiple clinical centers to detect the expression of METTL16. CCK-8, cell cycle, EdU and xenograft mouse model experiments were used to evaluate the proliferation effect of METTL16. Potential downstream pathways and mechanisms were explored via RNA sequencing, m6A sequencing, and bioinformatic analyses. Regulatory mechanisms were studied through methyltransferase inhibition, RIP, MeRIP‒qPCR assays. Results: We found that METTL16 expression was markedly downregulated in PDAC, and multivariate Cox regression analyses revealed that METTL16 was a protective factor for PDAC patients. We also demonstrated that METTL16 overexpression inhibited PDAC cell proliferation. Furthermore, we identified a METTL16-p21 signaling axis, with downregulation of METTL16 resulting in inhibition of CDKN1A (p21). Additionally, METTL16 silencing and overexpression experiments highlighted m6A modification alterations in PDAC. Conclusions: METTL16 plays a tumor-suppressive role and suppresses PDAC cell proliferation through the p21 pathway by mediating m6A modification. METTL16 may be a novel marker of PDAC carcinogenesis and target for the treatment of PDAC.
40
Rebecca L. Siegel, Kimberly D. Miller, Hannah E. Fuchs et al. · CA A Cancer Journal for Clinicians · 2022 · 18.2K citations · Full text
Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq
Dan Dominissini, Sharon Moshitch-Moshkovitz, Schraga Schwartz et al. · Nature · 2012 · 5K citations
Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons
Kate D. Meyer, Yogesh Saletore, Paul Zumbo et al. · Cell · 2012 · 4.3K citations · Full text
N6-methyladenosine Modulates Messenger RNA Translation Efficiency
Xiao Wang, Boxuan Zhao, Ian A. Roundtree et al. · Cell · 2015 · 3.6K citations · Full text
A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation
Jianzhao Liu, Yanan Yue, Dali Han et al. · Nature Chemical Biology · 2013 · 3.5K citations · Full text